| Guardant360 Liquid is Guardant Health’s expanded liquid biopsy that builds on the capabilities of the earlier Guardant360 CDx test. While Guardant360 CDx is an FDA-approved comprehensive genomic profiling (CGP) assay, Guardant360 Liquid is much more sensitive allowing detection of very low-frequency tumor DNA shed into the bloodstream, even when tissue is scant or heterogeneous. It identifies a wider range of cancer-related genetic changes giving your doctor a more comprehensive picture of your tumor’s genetics. Guardant360 Liquid evaluates key cancer-related genes, and genomic alterations, such as single nucleotide variants, insertions and deletions, copy number amplifications, and gene fusions. It also includes biomarkers like tumor mutation burden and microsatellite instability. In addition, it can detect small cell transformation unlike Guardant360 CDx. Liquid Guardant testing should be prioritized because of its high sensitivity that reduces false-negative results, increases the likelihood of finding an actionable driver, and can obviate the need for repeat invasive biopsies. https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid |
Understanding Guardant360 Liquid Biopsy
Guardant360 Liquid is an advanced liquid biopsy that can detect extremely small amounts of tumor DNA circulating in the bloodstream. This technology allows doctors to identify important genetic changes even when tissue biopsies are difficult to obtain.
